Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Scheiman

Showing results (241-250 of 254) with videos related to

Pageof 26
Sort By:
European Heart Journal|October 6, 2016
Randomized trial of switching from prescribed non-selective non-steroidal anti-inflammatory drugs to prescribed celecoxib: the Standard care vs. Celecoxib Outcome Trial (SCOT)Thomas M MacDonald, Chris J Hawkey, Ian Ford, et al.
Gut|December 15, 2010
Type of pain, pain-associated complications, quality of life, disability and resource utilisation in chronic pancreatitis: a prospective cohort studyDaniel K Mullady, Dhiraj Yadav, Stephen T Amann, et al.
The New England Journal of Medicine|April 13, 2012
A randomized trial of rectal indomethacin to prevent post-ERCP pancreatitisB Joseph Elmunzer, James M Scheiman, Glen A Lehman, et al.
The Lancet. Gastroenterology & Hepatology|November 30, 2019
Rectal indometacin dose escalation for prevention of pancreatitis after endoscopic retrograde cholangiopancreatography in high-risk patients: a double-blind, randomised controlled trialEvan L Fogel, Glen A Lehman, Paul Tarnasky, et al.
The Journal of Rheumatology|June 14, 2000
Analysis of the effect of COX-2 specific inhibitors and recommendations for their use in clinical practiceP E Lipsky, S B Abramson, F C Breedveld, et al.
Gastrointestinal Endoscopy|August 28, 2004
Acute pancreatitis after EUS-guided FNA of solid pancreatic masses: a pooled analysis from EUS centers in the United StatesMohamad A Eloubeidi, Frank G Gress, Thomas J Savides, et al.
Lancet (London, England)|January 14, 2024
Indomethacin with or without prophylactic pancreatic stent placement to prevent pancreatitis after ERCP: a randomised non-inferiority trialB Joseph Elmunzer, Lydia D Foster, Jose Serrano, et al.
Gastrointestinal Endoscopy|February 6, 2025
Thirty-day hospital admission following high-risk outpatient ERCP: incidence and analysis of risk factors based on a secondary analysis of the Stent Versus Indomethacin trial data setPatrick Yachimski, Jingwen Zhang, Gregory A Coté, et al.
The American Journal of Gastroenterology|August 29, 2024
Technical Factors Associated With the Benefit of Prophylactic Pancreatic Stent Placement During High-Risk Endoscopic Retrograde Cholangiopancreatography: A Secondary Analysis of the SVI Trial Data SetB Joseph Elmunzer, Jingwen Zhang, Gregory A Coté, et al.
Gastrointestinal Endoscopy|October 10, 2024
Impact of difficult biliary cannulation on post-ERCP pancreatitis: secondary analysis of the stent versus indomethacin trial datasetSamuel Han, Jingwen Zhang, Valerie Durkalski-Mauldin, et al.
Pageof 26

Showing results (241-250 of 254) with videos related to

Sort By:
Pageof 26
European Heart Journal|October 6, 2016
Randomized trial of switching from prescribed non-selective non-steroidal anti-inflammatory drugs to prescribed celecoxib: the Standard care vs. Celecoxib Outcome Trial (SCOT)Thomas M MacDonald, Chris J Hawkey, Ian Ford, et al.
Gut|December 15, 2010
Type of pain, pain-associated complications, quality of life, disability and resource utilisation in chronic pancreatitis: a prospective cohort studyDaniel K Mullady, Dhiraj Yadav, Stephen T Amann, et al.
The New England Journal of Medicine|April 13, 2012
A randomized trial of rectal indomethacin to prevent post-ERCP pancreatitisB Joseph Elmunzer, James M Scheiman, Glen A Lehman, et al.
The Lancet. Gastroenterology & Hepatology|November 30, 2019
Rectal indometacin dose escalation for prevention of pancreatitis after endoscopic retrograde cholangiopancreatography in high-risk patients: a double-blind, randomised controlled trialEvan L Fogel, Glen A Lehman, Paul Tarnasky, et al.
The Journal of Rheumatology|June 14, 2000
Analysis of the effect of COX-2 specific inhibitors and recommendations for their use in clinical practiceP E Lipsky, S B Abramson, F C Breedveld, et al.
Gastrointestinal Endoscopy|August 28, 2004
Acute pancreatitis after EUS-guided FNA of solid pancreatic masses: a pooled analysis from EUS centers in the United StatesMohamad A Eloubeidi, Frank G Gress, Thomas J Savides, et al.
Lancet (London, England)|January 14, 2024
Indomethacin with or without prophylactic pancreatic stent placement to prevent pancreatitis after ERCP: a randomised non-inferiority trialB Joseph Elmunzer, Lydia D Foster, Jose Serrano, et al.
Gastrointestinal Endoscopy|February 6, 2025
Thirty-day hospital admission following high-risk outpatient ERCP: incidence and analysis of risk factors based on a secondary analysis of the Stent Versus Indomethacin trial data setPatrick Yachimski, Jingwen Zhang, Gregory A Coté, et al.
The American Journal of Gastroenterology|August 29, 2024
Technical Factors Associated With the Benefit of Prophylactic Pancreatic Stent Placement During High-Risk Endoscopic Retrograde Cholangiopancreatography: A Secondary Analysis of the SVI Trial Data SetB Joseph Elmunzer, Jingwen Zhang, Gregory A Coté, et al.
Gastrointestinal Endoscopy|October 10, 2024
Impact of difficult biliary cannulation on post-ERCP pancreatitis: secondary analysis of the stent versus indomethacin trial datasetSamuel Han, Jingwen Zhang, Valerie Durkalski-Mauldin, et al.
Pageof 26